AOC3 and diabetic kidney disease: The results indicate that a low effect response (defined as below 50% VAP-1 inhibition) would be obtained on average in DKD patients by ASP8232 dosing below 0.3 mg, while a high response (above 90% VAP-1 inhibition) would be achieved by doses above 3 mg.